Skip Navigation

Dr. Baowei Fei recently granted an R01 from National Institute of Health.

06/01/2011

NIH R01: Molecular Image-Directed, 3D Ultrasound-Guided Biopsy System

Principal Investigator

  • Baowei Fei, PhD, EngD

Co-Investigators

  • David Schuster, MD; 
  • Weiping Yu, PhD;
  • Tian Liu, PhD;
  • Aaron Fenster, PhD;
  • Viraj Master, MD

Funding Organization

National Institute of Health (NIH)

Significance

Prostate cancer affects 1 in 6 men in the USA. Every man over the age of 45 is at risk for prostate cancer. Systematic transrectal ultrasound (TRUS)-guided biopsy is the standard method for a definitive diagnosis of prostate cancer. More than 1.2 million prostate biopsies are performed annually and the medical cost is more than two billion dollars each year. However, this technique has a significant sampling error and is characterized by low sensitivity (39-52%). The current biopsy approach can miss up to 30% of prostate cancers. As a negative biopsy does not preclude the possibility of a missed cancer, both the physicians and patients face challenges in making treatment decisions. This project is to develop a molecular image-directed, 3D ultrasound-guided system for targeted biopsy of the prostate. If completely developed, the multimodality molecular image-guided biopsy device will be able to improve prostate cancer detection. The image-guided system will be able to be used not only for biopsy but also for brachytherapy, radiofrequency thermal ablation, cryotherapy, and photodynamic therapy.